Exelixis unveils phase 1 trial results for cabozantinib in combination with nivolumab in advanced ge
Biopharmaceutical firm Exelixis has announced results from a phase 1 trial of cabozantinib in combination with nivolumab in patients with previously treated genitourinary tumors.
The findings will be presented during a poster discussion session (Abstract #774PD) on October 9 at the European Society for Medical Oncology (ESMO) 2016 Congress, which is being held in Copenhagen, October 7 – 11, 2016.
Click on this link for more information.
